PureTech Health (PRTC) Short term Debt (2021 - 2022)
PureTech Health (PRTC) reported Short term Debt of $5.2 million for Q4 2022, up 501.63% year-over-year from $857000.0 in Q4 2021, and up 501.63% quarter-over-quarter from $857000.0 in Q4 2021.
PureTech Health (PRTC) Short term Debt (2021 - 2022) Analysis & Trends
PureTech Health (PRTC) has 2 years of Short term Debt data on file, last reported at $5.2 million in Q4 2022.
- Short term Debt for Q4 2022 came in at $5.2 million, up 501.63% year-over-year; the trailing twelve-month figure through Dec 2022 was $5.2 million (up 501.63% YoY), and the FY2022 annual result was $5.2 million, up 501.63% from the prior year.
- Short term Debt climbed to $5.2 million in Q4 2022 per PRTC's latest filing, from $857000.0 in the prior quarter.
- Over five years, Short term Debt peaked at $5.2 million in Q4 2022 and troughed at $857000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 5.16 Mn |
| Dec 31, 2021 | 857,000.00 |